Drug search by name

Tagraxofusp-erzs and Capillary leak syndrome

Result of checking the interaction of drug Tagraxofusp-erzs and disease Capillary leak syndrome for safety when used together.

Check result:

Tagraxofusp-erzs <> Capillary leak syndrome

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Capillary leak syndrome (CLS), including life-threatening and fatal cases, has been reported among patients treated with tagraxofusp. Common signs and symptoms (incidence = 20%) associated with CLS include hypoalbuminemia, edema, weight gain, and hypotension. Before initiating therapy with tagraxofusp, ensure that the patient has adequate cardiac function and serum albumin is greater than or equal to 3.2 g/dL. During treatment, monitor serum albumin levels prior to the initiation of each dose of tagraxofusp and as indicated clinically thereafter, and assess patients for any signs or symptoms of CLS.

Tagraxofusp-erzs

Generic Name: tagraxofusp

Brand Name: Elzonris

Synonyms: Tagraxofusp

What is Tagraxofusp-erzs?